MX337907B - Ensayos biomarcadores para detectar o medir inhibicion de actividad quinasa tor. - Google Patents

Ensayos biomarcadores para detectar o medir inhibicion de actividad quinasa tor.

Info

Publication number
MX337907B
MX337907B MX2013001293A MX2013001293A MX337907B MX 337907 B MX337907 B MX 337907B MX 2013001293 A MX2013001293 A MX 2013001293A MX 2013001293 A MX2013001293 A MX 2013001293A MX 337907 B MX337907 B MX 337907B
Authority
MX
Mexico
Prior art keywords
detecting
kinase activity
tor kinase
measuring inhibition
biomarker assays
Prior art date
Application number
MX2013001293A
Other languages
English (en)
Other versions
MX2013001293A (es
Inventor
Shuichan Xu
Lilly Wong
jian-hua Ding
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MX2013001293A publication Critical patent/MX2013001293A/es
Publication of MX337907B publication Critical patent/MX337907B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención se refiere a el uso de un anticuerpo anti-p4EBP1 para la preparación de un equipo para detectar o medir la inhibición de la actividad de quinasa TOR in vitro en un sujeto, donde el anticuerpo anti-p4EBP1 es utilizado en citometría de flujo para medir la cantidad 4EBP1 fosforilada en una muestra biológica del sujeto antes y después de la administración de un inhibidor de quinasa TOR, en donde el inhibidor de quinasa TOR tiene la fórmula (II): o una sal, clatrato, solvato, estereoisómero, tautómero, o profármaco farmacéuticamente aceptable de los mismos, en donde: R1 es piridilo sustituido o no sustituido; R2 es H, alquilo de c C1-8 sustituido o no sustituido, cicloalquilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, heterociclilalquilo sustituido o no sustituido, aralquilo sustituido o no sustituido, o cicloalquilalquilo sustituido o no sustituido; y R3 es H, o un alquilo de C1-8 sustituido o no sustituido.
MX2013001293A 2010-07-30 2011-07-29 Ensayos biomarcadores para detectar o medir inhibicion de actividad quinasa tor. MX337907B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36945510P 2010-07-30 2010-07-30
PCT/US2011/045842 WO2012016113A1 (en) 2010-07-30 2011-07-29 Biomarker assays for detecting or measuring inhibition of tor kinase activity

Publications (2)

Publication Number Publication Date
MX2013001293A MX2013001293A (es) 2013-04-29
MX337907B true MX337907B (es) 2016-03-28

Family

ID=45527332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001293A MX337907B (es) 2010-07-30 2011-07-29 Ensayos biomarcadores para detectar o medir inhibicion de actividad quinasa tor.

Country Status (22)

Country Link
US (1) US20120028972A1 (es)
EP (1) EP2598885B1 (es)
JP (1) JP2013535684A (es)
KR (1) KR20130136970A (es)
CN (1) CN103119445B (es)
AU (1) AU2011282553B2 (es)
BR (1) BR112013002279A2 (es)
CA (1) CA2807147A1 (es)
CO (1) CO6680668A2 (es)
CR (1) CR20130070A (es)
EC (1) ECSP13012461A (es)
ES (1) ES2591135T3 (es)
MX (1) MX337907B (es)
MY (1) MY170983A (es)
NI (1) NI201300013A (es)
NZ (1) NZ606495A (es)
PH (1) PH12013500240A1 (es)
RU (1) RU2587040C2 (es)
SG (1) SG187659A1 (es)
UA (1) UA111724C2 (es)
WO (1) WO2012016113A1 (es)
ZA (1) ZA201300921B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR101978537B1 (ko) 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
TWI615143B (zh) 2012-02-24 2018-02-21 標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
CA2866872A1 (en) * 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
AU2013203714B2 (en) * 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
TW201521725A (zh) * 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
US9782427B2 (en) * 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
BR112015026292B1 (pt) * 2013-04-17 2022-04-12 Signal Pharmaceuticals, Llc Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
AU2014254052B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105358177B (zh) * 2013-04-17 2018-11-23 西格诺药品有限公司 包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症
EP3003313A1 (en) 2013-05-29 2016-04-13 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135298B2 (en) * 2003-03-26 2006-11-14 The Burnham Institute For Medical Research Screening assay for agents that alter target of Rapamycin activity
EP1899463A4 (en) * 2005-05-09 2009-11-25 Ariad Pharma Inc BIOMARKERS FOR EVALUATING THE PROBABILITY OF SENSITIVITY OF A TUMOR AGAINST A MTOR INHIBITOR
GB0509748D0 (en) * 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
EP2385053B1 (en) * 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
ATE543819T1 (de) * 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway

Also Published As

Publication number Publication date
EP2598885B1 (en) 2016-07-20
BR112013002279A2 (pt) 2018-04-24
CO6680668A2 (es) 2013-05-31
EP2598885A1 (en) 2013-06-05
NI201300013A (es) 2013-04-19
CN103119445B (zh) 2015-10-21
US20120028972A1 (en) 2012-02-02
CR20130070A (es) 2013-05-20
RU2587040C2 (ru) 2016-06-10
JP2013535684A (ja) 2013-09-12
MX2013001293A (es) 2013-04-29
WO2012016113A1 (en) 2012-02-02
ECSP13012461A (es) 2013-03-28
CN103119445A (zh) 2013-05-22
AU2011282553B2 (en) 2015-04-02
MY170983A (en) 2019-09-23
KR20130136970A (ko) 2013-12-13
RU2013108840A (ru) 2014-09-10
ES2591135T3 (es) 2016-11-25
PH12013500240A1 (en) 2013-04-01
ZA201300921B (en) 2014-04-30
CA2807147A1 (en) 2012-02-02
EP2598885A4 (en) 2014-03-26
UA111724C2 (uk) 2016-06-10
SG187659A1 (en) 2013-03-28
AU2011282553A1 (en) 2013-03-14
NZ606495A (en) 2014-08-29

Similar Documents

Publication Publication Date Title
MY170983A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
IL257824A (en) Quizzes based on cells and their use
GB2498163A (en) High-throughput immune sequencing
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
ZA201302022B (en) Nmr systems and methods for the detection of analytes
GB201218555D0 (en) Immunoassay using electrochemical detection
IL234385B (en) Methods and compositions for detecting multiple analytes with a single signal
EP4563709A3 (en) Methods and materials for assessing allelic imbalance
WO2012075069A3 (en) Signatures and determinants associated with cancer and methods of use thereof
PL2720816T3 (pl) Urządzenie do pomiaru grubości żużla
IL254651A0 (en) Immunological determination method for the detection of thrombin
WO2012071471A3 (en) Biosensing systems for measurement of lactose
UA103283C2 (ru) Способ выявления компонентов клеточной стенки дрожжей
EP2836610A4 (en) METHOD FOR MEASURING POLYMERASE ACTIVITY, USEFUL FOR SENSITIVE QUANTITATIVE MEASUREMENTS OF ANY POLYMERASE EXTENSION ACTIVITIES AND FOR DETERMINING THE PRESENCE OF LIVABLE CELLS
GB2486635B (en) Detecting key corruption
GB201113482D0 (en) Assay
HK1185411A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
TWM389739U (en) Hidden steel plate
WO2012061512A9 (en) Methods and materials for assessing prognostic subtypes
CA141261S (en) Measuring device for firearms
PL390760A1 (pl) Urządzenie do wykrywania obecności elektrolitu
GB201005177D0 (en) Detecting analytes
GB201005333D0 (en) Key fob combining coinholder, tape measure and compass
UA48805U (ru) Способ определения одинакового уровня концентрации аэроионов от двух рассеивающих| источников аэроионного излучения
HK1188563A (en) Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels

Legal Events

Date Code Title Description
FG Grant or registration